DK2188306T3 - Immunoglobulinkløvningsfragmenter som sygdoms-indikatorer og sammensætninger til påvisning og binding af sådanne - Google Patents
Immunoglobulinkløvningsfragmenter som sygdoms-indikatorer og sammensætninger til påvisning og binding af sådanne Download PDFInfo
- Publication number
- DK2188306T3 DK2188306T3 DK08782610.3T DK08782610T DK2188306T3 DK 2188306 T3 DK2188306 T3 DK 2188306T3 DK 08782610 T DK08782610 T DK 08782610T DK 2188306 T3 DK2188306 T3 DK 2188306T3
- Authority
- DK
- Denmark
- Prior art keywords
- igg
- antibody
- disease
- human
- fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
Claims (11)
1. Antistofsammensætning der omfatter mindst ét antistof der specifikt binder til et IgG-proteasekløvningsprodukt kendetegnet ved, at a) har molekylvægt der er sammenlignelig med en intakt pattedyr IgG under ikke-denaturerende betingelser og b) er adskillelig i to fragmenter der omfatter et antigenbindingsfragment på 135 kDa og et CH2-indeholdende fragment under denaturering men ikke-reducerende betingelser og c) hvor reagenset ikke reagerer med intakt IgG, og hvor antistoffet specifikt binder til et protease-specifikt kløvningssted i human IgGl produceret af IdeS, TCPPCPAPELLG.
2. Antistofsammensætningen ifølge krav 1, hvor antistoffet er: i) et polyklonalt antiserum; eller ii) mindst ét monoklonalt antistof.
3. Humant IgG proteasekløvningssted-peptidanalog bestående af TCPPCPAPELLG kovalent bundet til keyhole limpet hemocyanin via N-terminus.
4. Fremgangsmåde til fremstilling af antistofsammensætningen ifølge krav 1 under anvendelse af et ikke-humant dyr immuniseret med peptid-analogen ifølge krav 3, hvor reagenset er oprenset fra serum fra dette dyr ved præ-absorption på en human IgG-affinitetsmatrix.
5. Fremgangsmåde til påvisning afen sygdomsproces i et individ ved analyse af en vævsprøve fra individet, hvor fremgangsmåden omfatter påvisningen med antistofsammensætningen ifølge krav 1 af en IgG proteolytisk kløvet med IdeS kendetegnet ved a) har en molekylvægt der er sammenlignelig med et intakt pattedyr IgG under fysiologiske betingelser og b) er adskillelig i to fragmenter der omfatter et antigenbindingsfragment på 135 kDa og et CH2-indeholdende fragment under denaturering men ikke-reducerende betingelser.
6. Fremgangsmåden ifølge krav 5, hvor sygdommen er valgt fra en arthritisk sygdom, en malign sygdom, en infektionssygdom, og en vaskulær sygdom, såsom hvor sygdommen er rheumatoid arthritis, fx hvor sygdommen er rheumatoid arthritis og prøven er synovialvæske.
7. Fremgangsmåden ifølge krav 5, hvor prøven er blod eller et fraktionsprodukt deraf.
8. Fremgangsmåden ifølge krav 5, hvor påvisningen udføres på vævsprøver andre end en blodfraktion.
9. Fremgangsmåden ifølge krav 5, hvor påvisningsproceduren er valgt fra gruppen bestående af ELISA, immunohistokemisk farvning, og Western blotting.
10. Kit omfattende et reagens til påvisning af en sygdomsmarkør i væv fra et individ, hvilket reagens omfatter mindst ét antistof der specifikt binder til et kløvet IgG, hvilket antistof er i stand til at påvise et IgG-kløvningsprodukt kendetegnet ved at a) har molekylvægt der er sammenlignelig med en intakt pattedyr IgG under ikke-denaturerende betingelser og b) er adskillelig i to fragmenter der omfatter et antigenbindingsfragment på 135 kDa og et CH2-indeholdende fragment under denaturering men ikke-reducerende betingelser og c) hvor reagenset ikke reagerer med intakt IgG, og hvor antistoffet specifikt binder til et protease-specifikt kløvningssted i humant IgGl produceret af IdeS, TCPPCPAPELLG.
11. Antistofsammensætningen ifølge krav 1 eller krav 2 til anvendelse i terapi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95516207P | 2007-08-10 | 2007-08-10 | |
| PCT/US2008/072083 WO2009023457A1 (en) | 2007-08-10 | 2008-08-04 | Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2188306T3 true DK2188306T3 (da) | 2016-08-22 |
Family
ID=40351057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08782610.3T DK2188306T3 (da) | 2007-08-10 | 2008-08-04 | Immunoglobulinkløvningsfragmenter som sygdoms-indikatorer og sammensætninger til påvisning og binding af sådanne |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20090155280A1 (da) |
| EP (1) | EP2188306B1 (da) |
| JP (2) | JP5530356B2 (da) |
| KR (2) | KR101588276B1 (da) |
| CN (2) | CN103497254B (da) |
| AU (1) | AU2008287128B2 (da) |
| BR (1) | BRPI0814355A2 (da) |
| CA (1) | CA2696011A1 (da) |
| DK (1) | DK2188306T3 (da) |
| EA (1) | EA025220B1 (da) |
| ES (1) | ES2593791T3 (da) |
| HU (1) | HUE029649T2 (da) |
| IL (1) | IL203544A (da) |
| MX (1) | MX2010001616A (da) |
| NZ (1) | NZ582916A (da) |
| PL (1) | PL2188306T3 (da) |
| PT (1) | PT2188306T (da) |
| SG (1) | SG183701A1 (da) |
| WO (1) | WO2009023457A1 (da) |
| ZA (1) | ZA201001689B (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501907B2 (en) * | 2007-08-10 | 2013-08-06 | Janssen Biotech, Inc. | Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
| TWI583394B (zh) | 2009-10-23 | 2017-05-21 | 千禧製藥公司 | 抗-ｇｃｃ抗體分子及其相關之組合物及方法 |
| MX2012005006A (es) | 2009-10-29 | 2012-06-19 | Janssen Biotech Inc | Variantes de glicosilacion de anticuerpos. |
| US8041225B2 (en) * | 2009-12-21 | 2011-10-18 | General Electric Company | Contactless infrared data transmission for wind turbines |
| EP2640414A4 (en) * | 2010-11-19 | 2016-06-15 | Janssen Biotech Inc | VACCINE COMPOSITIONS WITH IMMUNOGLOBULIN SPLITTING FRAGMENTS |
| CN103403621B (zh) | 2010-12-23 | 2015-11-25 | 尤利塔股份公司 | 用于在大面积上产生纳米结构的系统和方法 |
| PT2654780T (pt) | 2010-12-23 | 2017-04-06 | Janssen Biotech Inc | Mutantes ativos de fc de anticorpos resistentes a proteases |
| KR102046435B1 (ko) * | 2012-04-27 | 2019-11-19 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-gcc 항체 분자 및 gcc-표적화 치료법에 대한 감수성을 평가하기 위한 그 용도 |
| BR112016014824A2 (pt) * | 2013-12-27 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | Método para purificar anticorpo que tem ponto isoelétrico baixo |
| BR112016023046A8 (pt) | 2014-04-04 | 2021-05-11 | Mayo Found Medical Education & Res | kit compreendendo anticorpos e agentes redutores |
| US11209439B2 (en) | 2015-09-24 | 2021-12-28 | Mayo Foundation For Medical Education And Research | Identification of immunoglobulin free light chains by mass spectrometry |
| US10955420B2 (en) * | 2016-09-07 | 2021-03-23 | Mayo Foundation For Medical Education And Research | Identification and monitoring of cleaved immunoglobulins by molecular mass |
| EP3681528A4 (en) | 2017-09-13 | 2021-07-21 | Mayo Foundation for Medical Education and Research | IDENTIFICATION AND MONITORING OF THE APOPTOSIS INHIBITOR OF MACROPHAGES |
| EP3720884A4 (en) * | 2017-12-07 | 2021-09-29 | Chugai Seiyaku Kabushiki Kaisha | ANTIBODIES, COMPOSITIONS FOR USE IN THE DETECTION OR DETERMINATION OF A POLYPEPTIDE IN A SAMPLE, AND METHODS OF DETECTING OR DETERMINING A POLYPEPTIDE IN A SAMPLE |
| US20210325380A1 (en) * | 2020-04-20 | 2021-10-21 | EnLiSense, LLC | Disease diagnostics using a multi-configurable sensing array |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0698097T3 (da) * | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| AUPM322393A0 (en) * | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US7129331B2 (en) * | 2000-05-31 | 2006-10-31 | Pestka Biomedical Laboratories, Inc. | Phosphorylated polypeptides and uses related thereto |
| GB0130228D0 (en) * | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
-
2008
- 2008-08-04 DK DK08782610.3T patent/DK2188306T3/da active
- 2008-08-04 AU AU2008287128A patent/AU2008287128B2/en not_active Ceased
- 2008-08-04 HU HUE08782610A patent/HUE029649T2/en unknown
- 2008-08-04 PL PL08782610T patent/PL2188306T3/pl unknown
- 2008-08-04 MX MX2010001616A patent/MX2010001616A/es active IP Right Grant
- 2008-08-04 PT PT87826103T patent/PT2188306T/pt unknown
- 2008-08-04 SG SG2012058665A patent/SG183701A1/en unknown
- 2008-08-04 KR KR1020107005265A patent/KR101588276B1/ko not_active IP Right Cessation
- 2008-08-04 EA EA201070236A patent/EA025220B1/ru not_active IP Right Cessation
- 2008-08-04 EP EP08782610.3A patent/EP2188306B1/en not_active Not-in-force
- 2008-08-04 KR KR1020157013122A patent/KR20150059813A/ko not_active Application Discontinuation
- 2008-08-04 JP JP2010520241A patent/JP5530356B2/ja not_active Expired - Fee Related
- 2008-08-04 WO PCT/US2008/072083 patent/WO2009023457A1/en active Application Filing
- 2008-08-04 CN CN201310054803.0A patent/CN103497254B/zh not_active Expired - Fee Related
- 2008-08-04 CA CA2696011A patent/CA2696011A1/en not_active Abandoned
- 2008-08-04 BR BRPI0814355-2A2A patent/BRPI0814355A2/pt not_active IP Right Cessation
- 2008-08-04 ES ES08782610.3T patent/ES2593791T3/es active Active
- 2008-08-04 US US12/185,333 patent/US20090155280A1/en not_active Abandoned
- 2008-08-04 NZ NZ582916A patent/NZ582916A/xx not_active IP Right Cessation
- 2008-08-04 CN CN200880102840.1A patent/CN101889021B/zh not_active Expired - Fee Related
-
2010
- 2010-01-27 IL IL203544A patent/IL203544A/en not_active IP Right Cessation
- 2010-03-09 ZA ZA2010/01689A patent/ZA201001689B/en unknown
-
2013
- 2013-10-30 JP JP2013225205A patent/JP2014058535A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008287128A1 (en) | 2009-02-19 |
| ZA201001689B (en) | 2011-06-29 |
| KR20150059813A (ko) | 2015-06-02 |
| JP2010536037A (ja) | 2010-11-25 |
| CN103497254A (zh) | 2014-01-08 |
| NZ582916A (en) | 2012-08-31 |
| WO2009023457A1 (en) | 2009-02-19 |
| EA201070236A1 (ru) | 2010-08-30 |
| PT2188306T (pt) | 2016-09-13 |
| MX2010001616A (es) | 2010-03-15 |
| EP2188306B1 (en) | 2016-06-29 |
| CA2696011A1 (en) | 2009-02-19 |
| ES2593791T3 (es) | 2016-12-13 |
| HUE029649T2 (en) | 2017-02-28 |
| KR101588276B1 (ko) | 2016-01-26 |
| JP5530356B2 (ja) | 2014-06-25 |
| CN101889021B (zh) | 2016-06-08 |
| AU2008287128B2 (en) | 2013-07-18 |
| SG183701A1 (en) | 2012-09-27 |
| EP2188306A1 (en) | 2010-05-26 |
| US20090155280A1 (en) | 2009-06-18 |
| CN103497254B (zh) | 2016-12-28 |
| CN101889021A (zh) | 2010-11-17 |
| EA025220B1 (ru) | 2016-12-30 |
| PL2188306T3 (pl) | 2017-01-31 |
| JP2014058535A (ja) | 2014-04-03 |
| KR20100059850A (ko) | 2010-06-04 |
| BRPI0814355A2 (pt) | 2015-01-27 |
| IL203544A (en) | 2015-07-30 |
| EP2188306A4 (en) | 2011-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2188306T3 (da) | Immunoglobulinkløvningsfragmenter som sygdoms-indikatorer og sammensætninger til påvisning og binding af sådanne | |
| Ryan et al. | Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid | |
| KR101333168B1 (ko) | 프로가스트린에 대한 모노클로날 항체 | |
| RU2657517C2 (ru) | Анализ адромедуллина и способы определения зрелого адромедуллина | |
| US20150376294A1 (en) | Anti-pad2 antibodies and treatment of autoimmune diseases | |
| US9481734B2 (en) | Immunoglobulin cleavage fragments and disease indicators and compositions for detecting and binding such | |
| Brezski et al. | Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs | |
| KR20120064072A (ko) | 콜라겐 네오에피토프 항체 | |
| Zahid et al. | Design and reshaping of an scFv directed against human platelet glycoprotein VI with diagnostic potential | |
| US20150355199A1 (en) | Agents, kits and methods for complement factor h-related protein 1 detection | |
| EP2985295A1 (en) | Antibodies specific for MMP9 | |
| JP7437511B2 (ja) | 腫瘍免疫抑制因子に不応性の操作されたモノクローナル抗体の組成物及び使用 | |
| CN113892031B (zh) | 混合检测PCT和Presepsin的试剂盒、方法以及应用 | |
| KR100842121B1 (ko) | Ｄ-다이머에 대한 단일클론 항체와 이를 이용한 ｄ-다이머및 교차결합성 피브린 또는 이를 포함하는 피브린 분해물검사용 진단시약 | |
| WO2019056991A1 (zh) | 单克隆抗体或其抗原结合片段及其用途 | |
| EP3856781A1 (en) | Antibodies against soluble bcma | |
| CN116997571A (zh) | 结合ccr9的治疗性结合分子 |